Literature DB >> 30844397

Ketamine: A Paradigm Shift for Depression Research and Treatment.

John H Krystal1, Chadi G Abdallah2, Gerard Sanacora3, Dennis S Charney4, Ronald S Duman5.   

Abstract

Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of the biology of depression. Neurobiological insights into ketamine efficacy shed new light on the mechanisms underlying antidepressant efficacy. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30844397      PMCID： PMC6560624          DOI： 10.1016/j.neuron.2019.02.005

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  9 in total

1.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

2.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

3.  Ketamine Treatment and Global Brain Connectivity in Major Depression.

Authors:  Chadi G Abdallah; Lynnette A Averill; Katherine A Collins; Paul Geha; Jaclyn Schwartz; Christopher Averill; Kaitlin E DeWilde; Edmund Wong; Alan Anticevic; Cheuk Y Tang; Dan V Iosifescu; Dennis S Charney; James W Murrough
Journal:  Neuropsychopharmacology       Date:  2016-09-08       Impact factor: 7.853

4.  Antidepressant Use Among Persons Aged 12 and Over:United States,2011-2014.

Authors:  Laura A Pratt; Debra J Brody; Qiuping Gu
Journal:  NCHS Data Brief       Date:  2017-08

5.  Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.

Authors:  Tung-Ping Su; Mu-Hong Chen; Cheng-Ta Li; Wei-Chen Lin; Chen-Jee Hong; Ralitza Gueorguieva; Pei-Chi Tu; Ya-Mei Bai; Chih-Ming Cheng; John H Krystal
Journal:  Neuropsychopharmacology       Date:  2017-05-11       Impact factor: 7.853

6.  The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects.

Authors:  Chadi G Abdallah; Henk M De Feyter; Lynnette A Averill; Lihong Jiang; Christopher L Averill; Golam M I Chowdhury; Prerana Purohit; Robin A de Graaf; Irina Esterlis; Christoph Juchem; Brian P Pittman; John H Krystal; Douglas L Rothman; Gerard Sanacora; Graeme F Mason
Journal:  Neuropsychopharmacology       Date:  2018-06-28       Impact factor: 7.853

7.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.

Authors:  Ronald S Duman; George K Aghajanian; Gerard Sanacora; John H Krystal
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

Review 8.  Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.

Authors:  John H Krystal; Gerard Sanacora; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2013-06-15       Impact factor: 13.382

9.  A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders.

Authors:  Samuel T Wilkinson; Mesut Toprak; Mason S Turner; Steven P Levine; Rachel B Katz; Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2017-07-01       Impact factor: 18.112
  9 in total
  80 in total

1.  Mood, psychomotor, and cognitive function in major depressive disorder: from biomarkers to rapid-acting antidepressants.

Authors:  Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-10       Impact factor: 5.270

Review 2.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

3.  Are NMDA and opioid receptors involved in the antidepressant actions of ketamine?

Authors:  Kenji Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-19       Impact factor: 11.205

4.  Primary cilia safeguard cortical neurons in neonatal mouse forebrain from environmental stress-induced dendritic degeneration.

Authors:  Seiji Ishii; Toru Sasaki; Shahid Mohammad; Hye Hwang; Edwin Tomy; Fahad Somaa; Nobuyuki Ishibashi; Hideyuki Okano; Pasko Rakic; Kazue Hashimoto-Torii; Masaaki Torii
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-21       Impact factor: 11.205

5.  Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors.

Authors:  Feng Yi; Subhrajit Bhattacharya; Charles M Thompson; Stephen F Traynelis; Kasper B Hansen
Journal:  J Physiol       Date:  2019-11-02       Impact factor: 5.182

6.  The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.

Authors:  Jennifer Swainson; Alexander McGirr; Pierre Blier; Elisa Brietzke; Stéphane Richard-Devantoy; Nisha Ravindran; Jean Blier; Serge Beaulieu; Benicio N Frey; Sidney H Kennedy; Roger S McIntyre; Roumen V Milev; Sagar V Parikh; Ayal Schaffer; Valerie H Taylor; Valérie Tourjman; Michael van Ameringen; Lakshmi N Yatham; Arun V Ravindran; Raymond W Lam
Journal:  Can J Psychiatry       Date:  2020-11-11       Impact factor: 4.356

Review 7.  Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants.

Authors:  Ronald S Duman; Satoshi Deyama; Manoela Viar Fogaça
Journal:  Eur J Neurosci       Date:  2019-12-20       Impact factor: 3.386

Review 8.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

9.  Frontal cortex genetic ablation of metabotropic glutamate receptor subtype 3 (mGlu3) impairs postsynaptic plasticity and modulates affective behaviors.

Authors:  Max E Joffe; Chiaki I Santiago; Sheryl Anne D Vermudez; Nicole M Fisher; Shalini Dogra; Colleen M Niswender; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2021-05-25       Impact factor: 7.853

Review 10.  Ketamine and the Future of Rapid-Acting Antidepressants.

Authors:  Lace M Riggs; Todd D Gould
Journal:  Annu Rev Clin Psychol       Date:  2021-02-09       Impact factor: 18.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.